<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FIBRICOR- fenofibric acid tablet </strong><br>Caraco Pharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use FIBRICOR<span class="Sup">®</span> (fenofibric acid) Tablets safely and effectively. See full prescribing information for FIBRICOR.<br><br>FIBRICOR<span class="Sup">®</span> (fenofibric acid) Tablets, for oral use <br>Initial U.S. Approval: 1993</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: </p>
<ul class="Disc">
<li>to reduce triglyceride (TG) levels in adult patients with severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>  (≥ 500 mg/dL) (<a href="#S1.1">1.1</a>).</li>
<li>to reduce elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (TC), low-density-lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), TG and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> (Apo) B and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in adult patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (<a href="#S1.2">1.2</a>).</li>
</ul>
<p class="Highlighta">Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (<a href="#S1.3">1.3</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>FIBRICOR may be taken without regards to meals (<a href="#S2.1">2.1</a>).</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>: 35 to 105 mg/day; the dose should be adjusted according to patient response (<a href="#S2.2">2.2</a>).</li>
<li>Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>: 105 mg/day (<a href="#S2.3">2.3</a>).</li>
<li>Renally impaired patients: Initial dose of 35 mg once daily (<a href="#S2.4">2.4</a>).</li>
<li>Geriatric patients: Select the dose on the basis of renal function (<a href="#S2.5">2.5</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral Tablets: 35 mg and 105 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Severe renal dysfunction, including patients receiving dialysis (<a href="#S4">4</a>)</li>
<li>Active liver disease (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span> (<a href="#S4">4</a>)</li>
<li>Nursing Mothers (<a href="#S4">4</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fenofibric acid or fenofibrate (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking fenofibrate. The risks of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> appears to be increased when fibrates are co-administered with a statin (with a significantly higher rate observed for gemfibrozil), particularly in elderly patients and patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> (<a href="#S5.2">5.2</a>).</li>
<li>Fenofibrate can increase serum transaminases. Monitor liver tests, including ALT, periodically during therapy (<a href="#S5.3">5.3</a>).</li>
<li>Fenofibrate can reversibly increase serum creatinine levels. Monitor renal function periodically in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (<a href="#S5.4">5.4</a>).</li>
<li>Fenofibrate increases <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to risk of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. If <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> is suspected, gallbladder studies are indicated (<a href="#S5.5">5.5</a>).</li>
<li>Exercise caution in concomitant treatment with oral coumarin anticoagulants. Adjust the dosage of coumarin anticoagulant to maintain the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR at the desired level to prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications (<a href="#S5.6">5.6</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (&gt; 2% and at least 1% greater than placebo) are abnormal liver tests, increased AST, increased ALT, increased CPK, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (<a href="#S6">6</a>).<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Coumarin Anticoagulants (<a href="#S7.1">7.1</a>)</li>
<li>Bile-Acid Binding Resins (<a href="#S7.2">7.2</a>)</li>
<li>Immunosuppressants (<a href="#S7.3">7.3</a>)</li>
<li>Colchicine (<a href="#S7.4">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Geriatric Use:  Determine dose selection based on renal function (<a href="#S8.5">8.5</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Avoid in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; dose reduction required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#S8.6">8.6</a>).</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Important Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	 General Considerations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 	Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> </a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Geriatric Patients</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Mortality and Coronary Heart Disease Morbidity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Skeletal Muscle</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Liver Function</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Serum Creatinine</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Coumarin Anticoagulants</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Hematological Changes</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Venothromboembolic Disease</a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Paradoxical Decreases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Coumarin Anticoagulants</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Bile-Acid Binding Resins</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Immunosuppressants</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Colchicine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">FIBRICOR is indicated as adjunctive therapy to diet for treatment of severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (≥ 500 mg/dL). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.</p>
<p>Markedly elevated levels of serum triglycerides &gt; 2000 mg/dL may increase the risk of developing <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></h2>
<p class="First">FIBRICOR is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (Total-C), triglycerides (TG), and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>), and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Important Limitations of Use</h2>
<p class="First">Fenofibrate at a dose equivalent to 105 mg of FIBRICOR was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	 General Considerations</h2>
<p class="First">FIBRICOR can be given without regard to meals. Patients should be advised to swallow FIBRICOR tablets whole. Do not crush, dissolve or chew tablets.</p>
<p>Patients should be placed on an appropriate lipid-lowering diet before receiving FIBRICOR and should continue this diet during treatment with fenofibric acid.</p>
<p>The initial treatment for <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, such as <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.</p>
<p>Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of FIBRICOR. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 105 mg per day.</p>
<p>Consideration should be given to reducing the dosage of FIBRICOR if lipid levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> significantly below the targeted range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 	Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">The initial dose is 35 to 105 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 105 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></h2>
<p class="First">The dose of FIBRICOR is 105 mg per day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span> </h2>
<p class="First">In patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, treatment with FIBRICOR should be initiated at a dose of 35 mg once daily, and increased only after evaluation of the effects on renal function and lipid levels at this dose. The use of FIBRICOR should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see <a href="#S8.6">Use in Specific Populations (8.6)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Geriatric Patients</h2>
<p class="First">Dose selection for the elderly should be made on the basis of renal function [<span class="Italics">see <a href="#S8.5">Use in Specific Populations (8.5)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li> 35-mg:  White, round tablets. Debossed "AR 787".</li>
<li> 105-mg: White, modified oval tablets. Debossed "AR 788".</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">FIBRICOR is contraindicated in:</p>
<ul class="Disc">
<li> patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those receiving dialysis [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</li>
<li> patients with active liver disease, including those with <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span> and unexplained persistent liver function abnormalities [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</li>
<li> patients with preexisting <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> [<span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a></span>].</li>
<li> patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fenofibric acid or fenofibrate [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>].</li>
<li> nursing mothers [<span class="Italics">see <a href="#S8.3">Use in Specific Populations (8.3)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Mortality and Coronary Heart Disease Morbidity</h2>
<p class="First">The effect of FIBRICOR on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.</p>
<p>The Action to Control Cardiovascular Risk in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus on background statin therapy treated with fenofibrate. The mean duration of follow-up was 4.7 years. Fenofibrate plus statin combination therapy showed a non-significant 8% relative risk reduction in the primary outcome of major adverse cardiovascular events (MACE), a composite of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and cardiovascular disease <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (hazard ratio [HR] 0.92, 95% CI 0.79–1.08) (p=0.32) as compared to statin monotherapy. In a gender subgroup analysis, the hazard ratio for MACE in men receiving combination therapy versus statin monotherapy was 0.82 (95% CI 0.69–0.99), and the hazard ratio for MACE in women receiving combination therapy versus statin monotherapy was 1.38 (95% CI 0.98–1.94) (interaction p=0.01). The clinical significance of this subgroup finding is unclear.</p>
<p>The Fenofibrate Intervention and Event Lowering in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (FIELD) study was a 5 year randomized, placebo-controlled study of 9795 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus treated with fenofibrate. Fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75–1.05, p=0.16) and a significant 11% reduction in the secondary outcome of total cardiovascular disease events (HR 0.89 [0.80–0.99], p=0.04). There was a non-significant 11% (HR 1.11 [0.95, 1.29], p=0.18) and 19% (HR 1.19 [0.90, 1.57], p=0.22) increase in total and coronary heart disease mortality, respectively, with fenofibrate as compared to placebo.</p>
<p>Because of chemical, pharmacological, and clinical similarities between fenofibrate, clofibrate, and gemfibrozil, the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to fenofibric acid.</p>
<p>In the Coronary Drug Project, a large study of post <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> and <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span> requiring surgery between the two groups (3.0% vs. 1.8%).</p>
<p>In a study conducted by the World Health Organization (WHO), 5000 subjects without known <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age – adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p&lt;0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. This appeared to confirm the higher risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> seen in clofibrate-treated patients studied in the Coronary Drug Project.</p>
<p>The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p=0.19, 95% confidence interval for relative risk = 0.91–1.64). Although cancer <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> trended higher in the gemfibrozil group (p=0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (relative risk=1.29).</p>
<p>A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> trended higher in the gemfibrozil group, this was not statistically significant (HR 2.2, 95% confidence interval: 0.94–5.05).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Skeletal Muscle</h2>
<p class="First">Fibrates increase the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and have been associated with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p>Data from observational studies suggest that the risk for <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased when fibrates, in particular gemfibrozil, are co-administered with an HMG-CoA reductase inhibitor (statin). The combination should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and/or marked elevations of creatine phosphokinase levels.</p>
<p>Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. CPK levels should be assessed in patients reporting these symptoms, and FIBRICOR therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> is suspected or diagnosed.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine [<span class="Italics">see <a href="#S7.4">Drug Interactions (7.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Liver Function</h2>
<p class="First">Fenofibrate (administered over a range of doses with the higher dose equivalent to 105 mg fenofibric acid) has been associated with increases in serum transaminases [AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) or ALT (SGPT)].</p>
<p>In a pooled analysis of 10 placebo-controlled trials, increases to &gt; 3 times the upper limit of normal of ALT occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.</p>
<p>When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases observed with fenofibrate therapy appear to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 35 mg to 105 mg FIBRICOR per day and was 0% in those receiving dosages equivalent to 35 mg or less FIBRICOR per day, or placebo.</p>
<p>Hepatocellular, chronic active and <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>.</p>
<p>Baseline and regular, periodic monitoring of liver function, including ALT (SGPT) should be performed for the duration of therapy with FIBRICOR, and therapy discontinued if enzyme levels persist above three times the normal limit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Serum Creatinine</h2>
<p class="First">Elevations in serum creatinine have been reported in patients on fenofibrate. These elevations tend to return to baseline following discontinuation of fenofibrate. The clinical significance of these observations is unknown. Renal monitoring should be considered for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and for patients at risk for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, such as the elderly and patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span></h2>
<p class="First">FIBRICOR, like fenofibrate, clofibrate and gemfibrozil, may increase <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. If <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> is suspected, gallbladder studies are indicated. FIBRICOR therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> are found.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Coumarin Anticoagulants</h2>
<p class="First">Caution should be exercised when coumarin anticoagulants are given in conjunction with FIBRICOR. FIBRICOR may potentiate the anticoagulant effects of these agents resulting in prolongation of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/International Normalized Ratio (PT/INR). To prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications, frequent monitoring of PT/INR and dose adjustment of the anticoagulant are recommended until the PT/INR has stabilized [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> has been reported in patients taking fenofibrate. This occurrence may represent a failure of efficacy in patients with severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Hematological Changes</h2>
<p class="First">Mild-to-moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported in individuals treated with fenofibrate. Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of FIBRICOR administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> requiring patient hospitalization and treatment with steroids have been reported in individuals treated with fenofibrate.</p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> was seen in 1.1 vs. 0%, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in 1.4 vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Venothromboembolic Disease</h2>
<p class="First">In the FIELD trial, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> (PE) and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) were observed at higher rates in the fenofibrate- than the placebo-treated group. Of 9,795 patients enrolled in FIELD, there were 4,900 in the placebo group and 4,895 in the fenofibrate group. For DVT, there were 48 events (1%) in the placebo group and 67 (1%) in the fenofibrate group (p=0.074); and for PE, there were 32 (0.7%) events in the placebo group and 53 (1%) in the fenofibrate group (p=0.022).</p>
<p>In the Coronary Drug Project, a higher proportion of the clofibrate group experienced definite or suspected fatal or nonfatal <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> than the placebo group (5.2% vs. 3.3% at five years; p&lt;0.01).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Paradoxical Decreases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels</h2>
<p class="First">There have been postmarketing and clinical trial reports of severe decreases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibrate therapy. The decrease in HDL-C is mirrored by a decrease in <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A1. This decrease has been reported to occur within 2 weeks to years after initiation of fibrate therapy. The HDL-C levels remain depressed until fibrate therapy has been withdrawn; the response to withdrawal of fibrate therapy is rapid and sustained. The clinical significance of this decrease in HDL-C is unknown. It is recommended that HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Adverse reactions reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials are listed in Table 1. Adverse reactions led to discontinuation of treatment in 5% of patients treated with fenofibrate and in 3% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1. Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> During the Double-Blind, Placebo-Controlled Trials</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">BODY SYSTEM</th>
<th class="Rrule" align="center">Fenofibrate<a href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Adverse Reactions</th>
<th class="Rrule" align="center">(N=439)</th>
<th class="Rrule" align="center">(N=365)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Fenofibric acid is the active moiety of fenofibrate; Fenofibrate dosage equivalent to 105 mg fenofibric acid.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Significantly different from Placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">BODY AS A WHOLE</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">4.6%</td>
<td class="Rrule" align="center">4.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Rrule" align="center">3.4%</td>
<td class="Rrule" align="center">2.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">3.2%</td>
<td class="Rrule" align="center">2.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">DIGESTIVE</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Abnormal Liver Function Tests</span></td>
<td class="Rrule" align="center">7.5%<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">1.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">1.9%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">1.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">METABOLIC AND NUTRITIONAL DISORDERS</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Increased ALT</td>
<td class="Rrule" align="center">3.0%</td>
<td class="Rrule" align="center">1.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Increased CPK</td>
<td class="Rrule" align="center">3.0%</td>
<td class="Rrule" align="center">1.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Increased AST</td>
<td class="Rrule" align="center">3.4%<a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">RESPIRATORY</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorder</span></td>
<td class="Rrule" align="center">6.2%</td>
<td class="Rrule" align="center">5.5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">1.1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of fenofibrate: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, cirrhosis, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, decreases in hemoglobin, decreases in hematocrit, white blood cell decreases, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and severely depressed HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Coumarin Anticoagulants</h2>
<p class="First">Potentiation of coumarin-type anticoagulant effects has been observed with prolongation of the PT/INR.</p>
<p>Caution should be exercised when coumarin anticoagulants are given in conjunction with FIBRICOR. The dosage of the anticoagulants should be reduced to maintain the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR at the desired level to prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications. Frequent <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR determinations are advisable until it has been definitely determined that the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR has stabilized [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Bile-Acid Binding Resins</h2>
<p class="First">Since bile-acid binding resins may bind other drugs given concurrently, patients should take FIBRICOR at least 1 hour before or 4 to 6 hours after taking a bile-acid binding resin to avoid impending its absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Immunosuppressants</h2>
<p class="First">Immunosuppressant agents such as cyclosporine and tacrolimus can produce <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs, including FIBRICOR, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using FIBRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Colchicine</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category C:</span>  Safety in pregnant women has not been established. There are no adequate and well controlled studies of fenofibrate in pregnant women. FIBRICOR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In female rats given oral dietary doses of 15, 75, and 300 mg/kg/day of fenofibrate from 15 days prior to mating through weaning, maternal toxicity was observed at 0.3 times the maximum recommended human dose (MRHD), based on body surface area comparisons; mg per m<span class="Sup">2</span>.</p>
<p>In pregnant rats given oral dietary doses of 14, 127, and 361 mg/kg/day from gestation day 6–15 during the period of organogenesis, adverse developmental findings were not observed at 14 mg/kg/day (less than 1 times the MRHD, based on body surface area comparisons; mg per m<span class="Sup">2</span>). At higher multiples of human doses evidence of maternal toxicity was observed.</p>
<p>In pregnant rabbits given oral gavage doses of 15, 150, and 300 mg/kg/day from gestation day 6–18 during the period of organogenesis and allowed to deliver, aborted litters were observed at 150 mg/kg/day (10 times the MRHD based on body surface area comparisons; mg per m<span class="Sup">2</span>). No developmental findings were observed at 15 mg/kg/day (less than 1 times the MRHD, based on body surface area comparisons; mg per m<span class="Sup">2</span>).</p>
<p>In pregnant rats given oral dietary doses of 15, 75, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), maternal toxicity was observed at less than 1 times the MRHD, based on body surface area comparisons; mg per m<span class="Sup">2</span> [<span class="Italics">see <a href="#S13.1">Nonclinical Toxicology (13.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">FIBRICOR should not be used by nursing mothers. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">FIBRICOR is substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Fenofibric acid exposure is not influenced by age. Since elderly patients have a higher incidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, dose selection for the elderly should be made on the basis of renal function [<span class="Italics">see </span><span class="Italics"><a href="#S2.5">Dosage and Administration (2.5)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>]. Elderly patients with normal renal function should require no dose modifications. Consider monitoring renal function in elderly patients taking FIBRICOR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The use of FIBRICOR should be avoided in patients who have severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>]. Dose reduction is required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see <a href="#S2.4">Dosage and Administration (2.4)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>]. Monitoring renal function in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The use of FIBRICOR has not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no specific treatment for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with FIBRICOR. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occur. If indicated, elimination of unabsorbed drug should be achieved by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage; usual precautions should be observed to maintain the airway. Because FIBRICOR is highly bound to plasma proteins, hemodialysis should not be considered.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">FIBRICOR is a lipid regulating agent available as tablets for oral administration. Each tablet contains 35 mg or 105 mg of fenofibric acid. The chemical name for fenofibric acid is 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid with the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3149443-4baf-429b-a751-4a34a27f0249&amp;name=fibricor-01.jpg"></div>
<p>Fenofibric acid is a white to almost white crystalline powder that is stable under ordinary conditions, and has a melting point of 179 – 183°C. Its empirical formula is C<span class="Sub">17</span>H<span class="Sub">15</span>ClO<span class="Sub">4</span> and molecular weight 318.75. Fenofibric acid is insoluble in water; its solubility increases with pH in buffered media.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<p class="First">Inactive Ingredients: Each tablet contains copovidone, crospovidone, magnesium stearate and microcrystalline cellulose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The active moiety of FIBRICOR is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate.</p>
<p>The  lipid-modifying effects of fenofibric acid seen in clinical practice have been explained <span class="Italics">in vivo</span> in transgenic mice and <span class="Italics">in vitro</span> in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting decrease in TG produces an alteration in the size and composition of LDL from small, dense particles to large buoyant particles. These larger particles have a greater affinity for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> receptors and are catabolized rapidly. Activation of PPARα also induces an increase in the synthesis of apoproteins A-I, A-II and HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p>Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, an LDL membrane complex, are associated with human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Similarly, decreased levels of HDL-C and its transport complex, <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A (apo AI and apo AII) are associated with the development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, LDL-C, and TG, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular morbidity and mortality has not been determined.</p>
<p>Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoproteins</span> apo AI and apo AII.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>The absolute bioavailability of FIBRICOR has not been determined as the compound is virtually insoluble in aqueous media suitable for injection. Following oral administration of FIBRICOR in healthy volunteers, median peak plasma levels of fenofibric acid occur by approximately 2.5 hours after administration. Exposure after administration of 3 × 35 mg FIBRICOR tablets is comparable to 1 × 105 mg FIBRICOR tablets.</p>
<p>A food-effect study involving administration of FIBRICOR to healthy volunteers under fasting conditions and with a high-fat meal indicated that the C<span class="Sub">max</span> was decreased by approximately 35% while the AUC remained unchanged. This decrease in exposure is not considered clinically significant, and therefore FIBRICOR can be taken without regards to meals.</p>
<p>The extent and rate of absorption of fenofibric acid after administration of 105 mg FIBRICOR tablets are equivalent to those after administration of 145 mg fenofibrate tablets (TriCor<span class="Sup">®</span>) under fasted conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Upon multiple dosing of fenofibrate, fenofibric acid steady state is achieved within 9 days. Plasma concentrations of fenofibric acid at steady state are slightly more than double those following a single dose. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> metabolism data indicate that fenofibric acid does not undergo oxidative metabolism (e.g. cytochrome P450) to a significant extent. The enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 do not play a role in the metabolism of fenofibric acid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>After absorption, fenofibric acid is eliminated with a half-life of approximately 20 hours, allowing once-daily dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Geriatrics:</span> In five elderly volunteers 77 to 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that an equivalent dose of FIBRICOR can be used in elderly subjects with normal renal function, without increasing accumulation of the drug or metabolites [<span class="Italics">see <a href="#S8.5">Use in Specific Populations (8.5)</a></span> and<span class="Italics"><a href="#S2.5"> Dosage and Administration (2.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Pediatrics</span><span class="Italics">:</span> The pharmacokinetics of FIBRICOR has not been studied in pediatric populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Gender:</span> No pharmacokinetic difference between males and females has been observed for fenofibrate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics">Race:</span> The influence of race on the pharmacokinetics of fenofibric acid has not been studied, however, fenofibric acid is not metabolized by enzymes known for exhibiting inter-ethnic variability.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetics of fenofibric acid was examined in patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Estimated glomerular filtration rate [eGFR]&lt;30 mL/min/1.73m<span class="Sup">2</span>) showed a 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects. Patients with mild-to-moderate (eGFR 30 – 59 mL/min/1.73m<span class="Sup">2</span>) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Based on these findings, the use of FIBRICOR should be avoided in patients who have severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and dose reduction is required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> No pharmacokinetic studies of fenofibric acid have been conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.7"></a><p></p>
<p class="First"><span class="Italics">Drug-Drug Interactions: In vitro</span> studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.</p>
<p>Table 2 describes the effects of co-administered drugs on fenofibric acid systemic exposure. Table 3 describes the effects of co-administered fenofibric acid on exposure to other drugs.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2. Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from FIBRICOR or Fenofibrate Administration</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="12%">
<thead>
<tr class="First">
<th align="left">Co-Administered Drug</th>
<th align="left">Dosage Regimen of Co-Administered Drug</th>
<th align="left">Dosage Regimen of Fenofibrate</th>
<th align="left" colspan="2">Changes in Fenofibric Acid Exposure</th>
</tr>
<tr class="Botrule Last">
<th align="left"></th>
<th align="left"></th>
<th align="left"></th>
<th align="left">AUC</th>
<th align="left">C<span class="Sub">max</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>TriCor<span class="Sup">®</span> (fenofibrate) oral tablet</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>TriCor<span class="Sup">®</span> (fenofibrate) oral micronized capsule</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td align="left" colspan="5"><span class="Bold">No dosing adjustment required for FIBRICOR with the following co-administered drugs</span></td></tr>
<tr>
<td align="left"><span class="Italics">Lipid-lowering agents</span></td>
<td align="left" colspan="4"></td>
</tr>
<tr>
<td align="left">Atorvastatin</td>
<td align="left">20 mg once daily for 10 days</td>
<td align="left">Fenofibrate 160 mg<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> once daily for 10 days</td>
<td align="left">↓2%</td>
<td align="left">↓4%</td>
</tr>
<tr>
<td align="left">Pravastatin</td>
<td align="left">40 mg as a single dose</td>
<td align="left">Fenofibrate 3 × 67 mg<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a> as a single dose</td>
<td align="left">↓1%</td>
<td align="left">↓2%</td>
</tr>
<tr>
<td align="left">Fluvastatin</td>
<td align="left">40 mg as a single dose</td>
<td align="left">Fenofibrate 160 mg<a href="#footnote-3" class="Sup">*</a> as a single dose</td>
<td align="left">↓2%</td>
<td align="left">↓10%</td>
</tr>
<tr>
<td align="left"><span class="Italics">Anti-diabetic agents</span></td>
<td align="left" colspan="4"></td>
</tr>
<tr>
<td align="left">Glimepiride</td>
<td align="left">1 mg as a single dose</td>
<td align="left">Fenofibrate 145 mg<a href="#footnote-3" class="Sup">*</a> once daily for 10 days</td>
<td align="left">↑1%</td>
<td align="left">↓1%</td>
</tr>
<tr>
<td align="left">Metformin</td>
<td align="left">850 mg three times daily for 10 days</td>
<td align="left">Fenofibrate 54 mg<a href="#footnote-3" class="Sup">*</a> three times daily for 10 days</td>
<td align="left">↓9%</td>
<td align="left">↓6%</td>
</tr>
<tr class="Botrule Last">
<td align="left">Rosiglitazone</td>
<td align="left">8 mg once daily for 5 days</td>
<td align="left">Fenofibrate 145 mg<a href="#footnote-3" class="Sup">*</a> once daily for 14 days</td>
<td align="left">↑10%</td>
<td align="left">↑3%</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="75%">
<caption><span>Table 3. Effects of FIBRICOR or Fenofibrate Co-Administration on Systemic Exposure of Other Drugs</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="12%">
<thead>
<tr class="First">
<th align="left">Dosage Regimen of Fenofibrate</th>
<th align="left">Dosage Regimen of Co-Administered Drug</th>
<th align="left" colspan="3">Change in Co-Administered Drug Exposure</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="left"></th>
<th align="left">Analyte</th>
<th align="left">AUC</th>
<th align="left">C<span class="Sub">max</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>TriCor<span class="Sup">®</span> (fenofibrate) oral tablet</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>TriCor<span class="Sup">®</span> (fenofibrate) oral micronized capsule</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td align="left" colspan="5"><span class="Bold">No dosing adjustment required for these co-administered drugs with FIBRICOR</span></td></tr>
<tr>
<td align="left"><span class="Italics">Lipid-lowering agents</span></td>
<td align="left" colspan="4"></td>
</tr>
<tr>
<td align="left">Fenofibrate 160 mg<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> once daily for 10 days</td>
<td align="left">Atorvastatin, 20 mg once daily for 10 days</td>
<td align="left">Atorvastatin</td>
<td align="left">↓17%</td>
<td align="left">0%</td>
</tr>
<tr>
<td align="left">Fenofibrate 3 × 67 mg<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a> as a single dose</td>
<td align="left">Pravastatin, 40 mg as a single dose</td>
<td align="left">Pravastatin</td>
<td align="left">↑13%</td>
<td align="left">↑13%</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left">3α-Hydroxyl-iso-pravastatin</td>
<td align="left">↑26%</td>
<td align="left">↑29%</td>
</tr>
<tr>
<td align="left">Fenofibrate 160 mg<a href="#footnote-5" class="Sup">*</a> once daily for 10 days</td>
<td align="left">Pravastatin, 40 mg once daily for 10 days</td>
<td align="left">Pravastatin</td>
<td align="left">↑28%</td>
<td align="left">↑36%</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left">3α-Hydroxyl-iso-pravastatin</td>
<td align="left">↑39%</td>
<td align="left">↑55%</td>
</tr>
<tr>
<td align="left">Fenofibrate 160 mg<a href="#footnote-5" class="Sup">*</a> as a single dose</td>
<td align="left">Fluvastatin, 40 mg as a single dose</td>
<td align="left">(+)-3R, 5S-Fluvastatin</td>
<td align="left">↑15%</td>
<td align="left">↑16%</td>
</tr>
<tr>
<td align="left"><span class="Italics">Anti-diabetic agents</span></td>
<td align="left" colspan="4"></td>
</tr>
<tr>
<td align="left">Fenofibrate 145 mg<a href="#footnote-5" class="Sup">*</a> once daily for 10 days</td>
<td align="left">Glimepiride, 1 mg as a single dose</td>
<td align="left">Glimepiride</td>
<td align="left">↑35%</td>
<td align="left">↑18%</td>
</tr>
<tr>
<td align="left">Fenofibrate 54 mg<a href="#footnote-5" class="Sup">*</a> three times daily for 10 days</td>
<td align="left">Metformin, 850 mg three times daily for 10 days</td>
<td align="left">Metformin</td>
<td align="left">↑3%</td>
<td align="left">↑6%</td>
</tr>
<tr>
<td align="left">Fenofibrate 145 mg<a href="#footnote-5" class="Sup">*</a> once daily for 14 days</td>
<td align="left">Rosiglitazone, 8 mg once daily for 5 days</td>
<td align="left">Rosiglitazone</td>
<td align="left">↑6%</td>
<td align="left">↓1%</td>
</tr>
<tr>
<td align="left"><span class="Italics">Anti-viral agents</span></td>
<td align="left" colspan="4"></td>
</tr>
<tr class="Botrule Last">
<td align="left">FIBRICOR 105 mg once daily for 10 days</td>
<td align="left">Efavirenz, 600 mg as a single dose</td>
<td align="left">Efavirenz</td>
<td align="left">↓8%</td>
<td align="left">↑1%</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. In the first 24-month study, Wistar rats were dosed with fenofibrate at 10, 45, and 200 mg/kg/day, approximately 0.3, 1, and 6 times the maximum recommended human (MRHD) dose, based on body surface area comparisons (mg/m<span class="Sup">2</span>). At a dose of 200 mg/kg/day (6 times the MRHD), the incidence of <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> was significantly increased in both sexes. A statistically significant increase in pancreatic carcinomas was observed in males at 1, and 6 times the MRHD; an increase in <span class="product-label-link" type="condition" conceptid="4243445" conceptname="Benign neoplasm of pancreas">pancreatic adenomas</span> and benign testicular interstitial cell tumors was observed at 6 times the MRHD in males. In a second 24-month rat carcinogenicity study in a different <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rats (Sprague-Dawley), doses of 10 and 60 mg/kg/day (0.3 and 2 times the MRHD) produced significant increases in the incidence of pancreatic acinar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in both sexes and increases in testicular interstitial cell tumors in males at 2 times the MRHD.</p>
<p>A 117-week carcinogenicity study was conducted in rats comparing three drugs: fenofibrate 10 and 60 mg/kg/day (0.3 and 2 times the MRHD of fenofibrate), clofibrate (400 mg/kg/day; 2 times the human dose), and gemfibrozil (250 mg/kg/day; 2 times the human dose, based on mg/meter<span class="Sup">2</span> surface area). Fenofibrate increased pancreatic acinar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in both sexes. Clofibrate increased hepatocellular carcinoma and pancreatic acinar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males and hepatic neoplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> in females. Gemfibrozil increased hepatic neoplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> in males and females, while all three drugs increased testicular interstitial cell tumors in males.</p>
<p>In a 21-month study in CF-1 mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 1, and 3 times the human dose on the basis of mg/sq meter surface area) significantly increased the <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> in both sexes at doses that result in exposure to fenofibric acid that is 3 times the MRHD. In a second 18-month study at 10, 60, and 200 mg/kg/day, fenofibrate significantly increased the <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> in male mice and liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female mice at 3 times the MRHD of fenofibrate.</p>
<p>Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, chromosomal aberration and unscheduled DNA synthesis in primary rat hepatocytes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>In fertility studies, rats were given oral dietary doses of fenofibrate. Males received 61 days prior to mating and females 15 days prior to mating through weaning which resulted in no adverse effect on fertility at doses up to 300 mg/kg/day (approximately 10 times the MRHD of fenofibrate, based on mg/m<span class="Sup">2 </span>surface area comparisons).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients. Patients were treated for eight weeks under protocols that differed only in that one protocol entered patients with baseline triglyceride (TG) levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and normal cholesterolemia with or without hyperchylomicronemia, treatment with fenofibrate at dosages equivalent to 105 mg of FIBRICOR decreased primarily very low density lipoprotein (VLDL) triglycerides and VLDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Treatment of some with elevated triglycerides often results in an increase of low density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (see <a href="#table4">Table 4</a>).</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4. Effects of Fenofibrate in Patients with Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></span></caption>
<col align="left" valign="bottom" width="22%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="6%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="11%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd> = p &lt; 0.05 vs. Placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Study 1</span></td>
<td class="Rrule" align="center" colspan="4"><span class="Bold">Placebo</span></td>
<td class="Rrule" align="center" colspan="4"><span class="Bold">Fenofibrate</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline TG levels 350 to 499 mg/dL</td>
<td class="Rrule" align="center" valign="middle">N</td>
<td class="Rrule" align="center">Baseline (Mean)</td>
<td class="Rrule" align="center">Endpoint (Mean)</td>
<td class="Rrule" align="center">% Change (Mean)</td>
<td class="Rrule" align="center" valign="middle">N</td>
<td class="Rrule" align="center">Baseline (Mean)</td>
<td class="Rrule" align="center">Endpoint (Mean)</td>
<td class="Rrule" align="center">% Change (Mean)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Triglycerides</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">449</td>
<td class="Rrule" align="center">450</td>
<td class="Rrule" align="center">-0.5</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">432</td>
<td class="Rrule" align="center">223</td>
<td class="Rrule" align="center">-46.2<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">VLDL Triglycerides</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">367</td>
<td class="Rrule" align="center">350</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">350</td>
<td class="Rrule" align="center">178</td>
<td class="Rrule" align="center">-44.1<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">255</td>
<td class="Rrule" align="center">261</td>
<td class="Rrule" align="center">2.8</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">252</td>
<td class="Rrule" align="center">227</td>
<td class="Rrule" align="center">-9.1<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">19.6<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">120</td>
<td class="Rrule" align="center">129</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">128</td>
<td class="Rrule" align="center">137</td>
<td class="Rrule" align="center">14.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">VLDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">5.8</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">92</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">-44.7<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Study 2</span></td>
<td class="Rrule" align="center" colspan="4"><span class="Bold">Placebo</span></td>
<td class="Rrule" align="center" colspan="4"><span class="Bold">Fenofibrate</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline TG levels 500 to 1500 mg/dL</td>
<td class="Rrule" align="center" valign="middle">N</td>
<td class="Rrule" align="center">Baseline (Mean)</td>
<td class="Rrule" align="center">Endpoint (Mean)</td>
<td class="Rrule" align="center">% Change (Mean)</td>
<td class="Rrule" align="center" valign="middle">N</td>
<td class="Rrule" align="center">Baseline (Mean)</td>
<td class="Rrule" align="center">Endpoint (Mean)</td>
<td class="Rrule" align="center">% Change (Mean)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Triglycerides</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">710</td>
<td class="Rrule" align="center">750</td>
<td class="Rrule" align="center">7.2</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">726</td>
<td class="Rrule" align="center">308</td>
<td class="Rrule" align="center">-54.5<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">VLDL Triglycerides</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">537</td>
<td class="Rrule" align="center">571</td>
<td class="Rrule" align="center">18.7</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">543</td>
<td class="Rrule" align="center">205</td>
<td class="Rrule" align="center">-50.6<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">272</td>
<td class="Rrule" align="center">271</td>
<td class="Rrule" align="center">0.4</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">261</td>
<td class="Rrule" align="center">223</td>
<td class="Rrule" align="center">-13.8<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">5.0</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">22.9<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">90</td>
<td class="Rrule" align="center">-4.2</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">103</td>
<td class="Rrule" align="center">131</td>
<td class="Rrule" align="center">45.0<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">VLDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">137</td>
<td class="Rrule" align="center">142</td>
<td class="Rrule" align="center">11.0</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">126</td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">-49.4<a href="#footnote-7" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></h2>
<p class="First">The effects of fenofibrate at doses equivalent to 105 mg of FIBRICOR were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: Total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. Fenofibrate therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. Fenofibrate therapy also lowered triglycerides and raised HDL-C (see <a href="#table5">Table 5</a>).</p>
<a name="table5"></a><table width="75%">
<caption><span>Table 5. Mean Percent Change in Lipid Parameters at End of Fenofibrate Treatment<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="28%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Treatment Group</th>
<th class="Rrule" align="center">Total-C</th>
<th class="Rrule" align="center">LDL-C</th>
<th class="Rrule" align="center">HDL-C</th>
<th class="Rrule" align="center">TG</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Duration of study treatment was 3 to 6 months.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>p = &lt; 0.05 vs. Placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Pooled Cohort</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Mean baseline lipid values (n=646)</td>
<td class="Rrule" align="center">306.9 mg/dL</td>
<td class="Rrule" align="center">213.8 mg/dL</td>
<td class="Rrule" align="center">52.3 mg/dL</td>
<td class="Rrule" align="center">191.0 mg/dL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  All FEN (n=361)</td>
<td class="Rrule" align="center">-18.7%<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-20.6%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">+11.0%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-28.9%<a href="#footnote-9" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Placebo (n=285)</td>
<td class="Rrule" align="center">-0.4%</td>
<td class="Rrule" align="center">-2.2%</td>
<td class="Rrule" align="center">+0.7%</td>
<td class="Rrule" align="center">+7.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline LDL-C &gt;160 mg/dL and TG &lt;150 mg/dL (Type IIa)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Mean baseline lipid values (n=334)</td>
<td class="Rrule" align="center">307.7 mg/dL</td>
<td class="Rrule" align="center">227.7 mg/dL</td>
<td class="Rrule" align="center">58.1 mg/dL</td>
<td class="Rrule" align="center">101.7 mg/dL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  All FEN (n=193)</td>
<td class="Rrule" align="center">-22.4%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-31.4%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">+9.8%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-23.5%<a href="#footnote-9" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Placebo (n=141)</td>
<td class="Rrule" align="center">+0.2%</td>
<td class="Rrule" align="center">-2.2%</td>
<td class="Rrule" align="center">+2.6%</td>
<td class="Rrule" align="center">+11.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline LDL-C &gt;160 mg/dL and TG ≥150 mg/dL (Type IIb)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Mean baseline lipid values (n=242)</td>
<td class="Rrule" align="center">312.8 mg/dL</td>
<td class="Rrule" align="center">219.8 mg/dL</td>
<td class="Rrule" align="center">46.7 mg/dL</td>
<td class="Rrule" align="center">231.9 mg/dL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  All FEN (n=126)</td>
<td class="Rrule" align="center">-16.8%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-20.1%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">+14.6%<a href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-35.9%<a href="#footnote-9" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Placebo (n=116)</td>
<td class="Rrule" align="center">-3.0%</td>
<td class="Rrule" align="center">-6.6%</td>
<td class="Rrule" align="center">+2.3%</td>
<td class="Rrule" align="center">+0.9%</td>
</tr>
</tbody>
</table>
<p>In a subset of the subjects, measurement of <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> was conducted. Fenofibrate treatment significantly reduced <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> from baseline to endpoint as compared with placebo (-25.1% vs. 2.4%, p &lt; 0.0001, n=213 and 143 respectively).</p>
<p>The effect of FIBRICOR on cardiovascular morbidity and mortality has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">FIBRICOR<span class="Sup">®</span> (fenofibric acid) Tablets 35 mg, are white, round tablets, debossed "AR 787" on one side and blank on the other side.</p>
<table class="Noautorules" width="40%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left">Bottles of 30</td>
<td align="right">NDC 49708-101-07</td>
</tr></tbody>
</table>
<p>FIBRICOR<span class="Sup">®</span> (fenofibric acid) Tablets 105 mg, are white, modified oval tablets, debossed "AR 788" on one side and blank on the other side.</p>
<table class="Noautorules" width="40%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="left">Bottles of 30</td>
<td align="right">NDC 49708-102-07</td>
</tr>
<tr>
<td align="left">Bottles of 90</td>
<td align="right">NDC 49708-102-90</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 20° to 25°C (68° to 77°F).</p>
<p>[See USP Controlled Room Temperature]</p>
<p>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised:</p>
<ul class="Disc">
<li>of the potential benefits and risks of FIBRICOR.</li>
<li>not to use FIBRICOR if there is a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fenofibrate or fenofibric acid.</li>
<li>that if they are taking coumarin anticoagulants, FIBRICOR may increase their anticoagulant effect, and increased monitoring may be necessary.</li>
<li>of medications that should not be taken in combination with FIBRICOR.</li>
<li>to continue to follow an appropriate lipid-modifying diet while taking FIBRICOR.</li>
<li>to take FIBRICOR once daily, without regard to food, at the prescribed dose, swallowing each tablet whole.</li>
<li>to inform their physician of all medications, supplements, and herbal preparations they are taking and any change to their medical condition. Patients should also be advised to inform their physicians prescribing a new medication that they are taking FIBRICOR.</li>
<li>to inform their physician of any <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; onset of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; or any other new symptoms.</li>
<li>to return to their physician's office for routine monitoring.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">TriCor<span class="Sup">® </span>is a registered trademark of Abbott Laboratories.</p>
<p>FIBRICOR<span class="Sup">® </span>is a registered U.S. trademark of the URL Pharma, Inc. group of companies.</p>
<p>U.S. Patent Nos. 7,569,612 and other patents pending.</p>
<p><span class="Bold">Distributed by: Sun Pharmaceutical Industries, Inc.<br>      Cranbury, NJ 08512</span></p>
<p>Rev 03, November 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 35 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 49708-<span class="Bold">101</span>-07</p>
<p><span class="Bold">30 TABLETS</span></p>
<p><span class="Bold">FIBRICOR</span><span class="Sup">®</span><br>(fenofibric acid) Tablets</p>
<p><span class="Bold">35 mg</span></p>
<p>Rx Only</p>
<p><span class="Bold">SUN<br></span>PHARMA 						</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 35 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3149443-4baf-429b-a751-4a34a27f0249&amp;name=fibricor-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 105 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 49708-<span class="Bold">102</span>-07</p>
<p><span class="Bold">30 TABLETS</span></p>
<p><span class="Bold">FIBRICOR</span><span class="Sup">®</span><br>(fenofibric acid) Tablets</p>
<p><span class="Bold">105 mg</span></p>
<p>Rx Only</p>
<p><span class="Bold">SUN<br></span>PHARMA 						</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 105 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3149443-4baf-429b-a751-4a34a27f0249&amp;name=fibricor-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FIBRICOR 		
					</strong><br><span class="contentTableReg">fenofibric acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49708-101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Fenofibric Acid</strong> (Fenofibric Acid) </td>
<td class="formItem">Fenofibric Acid</td>
<td class="formItem">35 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Copovidone K25-31</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AR;787</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49708-101-07</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022418</td>
<td class="formItem">08/14/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FIBRICOR 		
					</strong><br><span class="contentTableReg">fenofibric acid tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49708-102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Fenofibric Acid</strong> (Fenofibric Acid) </td>
<td class="formItem">Fenofibric Acid</td>
<td class="formItem">105 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Copovidone K25-31</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Modified Oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AR;788</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49708-102-07</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49708-102-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022418</td>
<td class="formItem">08/14/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Caraco Pharma, Inc.
							(831527945)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mutual Pharmaceutical Company, Inc.</td>
<td class="formItem"></td>
<td class="formItem">121735955</td>
<td class="formItem">MANUFACTURE(49708-101, 49708-102), ANALYSIS(49708-101, 49708-102)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mutual Pharmaceutical Company, Inc.</td>
<td class="formItem"></td>
<td class="formItem">831656777</td>
<td class="formItem">MANUFACTURE(49708-101, 49708-102), LABEL(49708-101, 49708-102), PACK(49708-101, 49708-102)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7a94885b-62b6-4db9-8d01-f594be8dba13</div>
<div>Set id: b3149443-4baf-429b-a751-4a34a27f0249</div>
<div>Version: 2</div>
<div>Effective Time: 20150123</div>
</div>
</div> <div class="DistributorName">Caraco Pharma, Inc.</div></p>
</body></html>
